HomeSearch

NewsATHENEX Announces the Launch of the Novel Non-Frozen Ready-To-Use Bivalirudin

Athenex, Inc. (NASDAQ: ATNX), a leading global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the launch of a Ready-to-Use (RTU) Bivalirudin Injection through its subsidiary Athenex Pharmaceutical Division (APD). Bivalirudin RTU Injection is indicated for use as an anticoagulant in patients undergoing percutaneous...